Jakubowitz Law

NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Provention Bio, Inc. (NASDAQ:PRVB)

CONTACT JAKUBOWITZ ABOUT PRVB:
https://claimyourloss.com/securities/provention-bio-inc-loss-submission-form/?id=17681&from=1

Class Period : November 2, 2020 - April 8, 2021

Lead Plaintiff Deadline : July 20, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Athira Pharma, Inc. (NASDAQ:ATHA)

CONTACT JAKUBOWITZ ABOUT ATHA:
https://claimyourloss.com/securities/athira-pharma-inc-loss-submission-form/?id=17681&from=1

This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.

Lead Plaintiff Deadline : August 24, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

360 DigiTech, Inc. (NASDAQ:QFIN)

CONTACT JAKUBOWITZ ABOUT QFIN:
https://claimyourloss.com/securities/360-digitech-inc-loss-submission-form/?id=17681&from=1

Class Period : April 29, 2021 - July 7, 2021

Lead Plaintiff Deadline : September 13, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:
https://www.accesswire.com/655713/LAWSUITS-FILED-AGAINST-PRVB-ATHA-and-QFIN--Jakubowitz-Law-Pursues-Shareholders-Claims

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.